X-108440165-T-G
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_ModerateBS2
The NM_033380.3(COL4A5):āc.40T>Gā(p.Leu14Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000119 in 1,096,636 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 5 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. 15/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Consequence
NM_033380.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
COL4A5 | NM_033380.3 | c.40T>G | p.Leu14Val | missense_variant | 1/53 | ENST00000328300.11 | |
COL4A5 | NM_000495.5 | c.40T>G | p.Leu14Val | missense_variant | 1/51 | ||
COL4A5 | XM_047441811.1 | c.40T>G | p.Leu14Val | missense_variant | 1/42 | ||
COL4A5 | XM_047441810.1 | c.-337T>G | 5_prime_UTR_variant | 1/54 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
COL4A5 | ENST00000328300.11 | c.40T>G | p.Leu14Val | missense_variant | 1/53 | 1 | NM_033380.3 |
Frequencies
GnomAD3 genomes Cov.: 20
GnomAD3 exomes AF: 0.00000551 AC: 1AN: 181494Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 66228
GnomAD4 exome AF: 0.0000119 AC: 13AN: 1096636Hom.: 0 Cov.: 29 AF XY: 0.0000138 AC XY: 5AN XY: 362052
GnomAD4 genome Cov.: 20
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Sep 18, 2019 | The p.Leu14Val variant in COL4A5 has not been previously reported in individuals with Alport syndrome but has been identified in 0.001% (1/81016) of European chromosomes by gnomAD (http://gnomad.broadinstitute.org). Computational prediction tools and conservation analysis suggest that this variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In summary, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PM2, BP4. - |
X-linked Alport syndrome Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 10, 2020 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at